Laboratory Corp. of America Holdings

Laboratory Corporation of America Holdings is a life sciences company engaged in providing clinical laboratory and end-to-end drug development services. The company reports its business in two segments: LabCorp Diagnostics, which provides a menu of testing through an integrated network of primary and specialty laboratories across the U.S., supported by an information technology system, logistics, local labs providing testing, and also provides patient access points located throughout the U.S.; and Covance Drug Development, which provides end-to-end drug development, medical device and diagnostic development solutions from early-stage research to clinical development and commercial market access.
  • TickerLH
  • ISINUS50540R4092
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States
Valens Research

Valens Equity Insights and Inflections - 2020 09 15

ALGN currently trades well above averages relative to Uniform earnings, with a 72.6x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to improve from 35% in 2019 to 39% in 2024, accompanied by 20% Uniform asset growth going forward. That said, analysts have more bearish expectations, projecting Uniform ROA to compress to 10% in 2020 amid coronavirus headwinds, before recovering to 29% in 2021, accompanied by 6% Uniform asset growth. Furthermore, management appears concerned about their digital platform, Invisalign, and margins. Current valuations appear to be...

Valens Research

LH - Embedded Expectations Analysis - 2020 09 14

Laboratory Corporation of America Holdings (LH:USA) currently trades below corporate averages relative to UAFRS (Uniform) earnings, with a 20.5x Uniform P/E. Although management has bearish expectations for the firm, management is confident about its testing capacity and antibody testing value Specifically, management is confident about the growth of their coronavirus testing capacity, the efficacy of their antibody testing in helping accelerate vaccine evaluation, and that coronavirus testing is partially offsetting other losses

LAB CORP OF AMERICA reduces its risk exposure and slightly improves to Neutral

The independent financial analyst theScreener just allocated a lower risk rating to LAB CORP OF AMERICA (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date July 24, 2020, the closing price was USD 198.74 and its expected value was estimated at USD 175.76.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Getting Long-Term Oversold Note: We have suspended the Russell grids and Sector comments this week due to heightened volatility. Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward. Clues that a breakdown was increasingly likely started coming as early as Thursday, when the KBW Bank index broke below key $89 support we outlined last week. Friday's widening move in h...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • No one knows just how the COVID-19 plays out, but yes, at some point this too will pass. We would expect volatility to continue and headlines to trump (pun not intended) trends. The divergence between Technology and the Energy, Materials, and Industrials Sectors has been disturbing to us for some time. Small-Caps and emerging markets have been lagging the Tech heavy S&P 500 significantly as well. • We believe that widening spreads between high-yield corporates and 10-yr Treasuries could be the canary in the coal mine. A decisive break above the trend line may usher in a mu...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Laboratory Corp Of America Holdings: 1 director sold

A director at Laboratory Corp Of America Holdings sold 31,250 shares at 160.000USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

Valens Research

Valens Equity Insights and Inflections - 2020 09 15

ALGN currently trades well above averages relative to Uniform earnings, with a 72.6x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to improve from 35% in 2019 to 39% in 2024, accompanied by 20% Uniform asset growth going forward. That said, analysts have more bearish expectations, projecting Uniform ROA to compress to 10% in 2020 amid coronavirus headwinds, before recovering to 29% in 2021, accompanied by 6% Uniform asset growth. Furthermore, management appears concerned about their digital platform, Invisalign, and margins. Current valuations appear to be...

Valens Research

LH - Embedded Expectations Analysis - 2020 09 14

Laboratory Corporation of America Holdings (LH:USA) currently trades below corporate averages relative to UAFRS (Uniform) earnings, with a 20.5x Uniform P/E. Although management has bearish expectations for the firm, management is confident about its testing capacity and antibody testing value Specifically, management is confident about the growth of their coronavirus testing capacity, the efficacy of their antibody testing in helping accelerate vaccine evaluation, and that coronavirus testing is partially offsetting other losses

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Valens Research

Valens Equity Insights and Inflections - 2020 06 23

AMKR currently trades at a discount to Uniform assets, with a 0.6x Uniform P/B (V/A'). At these levels, the market is pricing in expectations for Uniform ROA to improve from immaterial levels in 2019 to just 3% through 2024, accompanied by 4% Uniform asset growth going forward. Meanwhile, analysts have similarly muted expectations, projecting Uniform ROA to expand to 3% by 2021, accompanied by 2% Uniform asset shrinkage. That said, management is excited about their cost reduction actions and confident about their long-term growth strategy. Current valuations appear to be pricing in overly bear...

Moody's assigns Baa2 rating to LabCorp notes offering

Rating Action: Moody's assigns Baa2 rating to LabCorp notes offering. Global Credit Research- 19 Nov 2019. New York, November 19, 2019-- Moody's Investors Service assigned a Baa2 rating to the proposed offering of senior unsecured notes of Laboratory Corporation of America Holdings.

Laboratory Corporation of America Holdings: Update to credit analysis

LabCorp's credit profile is supported by the company's significant market presence and moderate leverage.

Laboratory Corporation of America Holdings: Update to credit analysis

LabCorp's credit profile is supported by the company's significant market presence and moderate leverage.

Moody's: LabCorp's Divestiture of Food Solutions Business is Credit Positive

Moody's Investors Service commented that the announcement by Laboratory Corporation of America Holdings ("LabCorp") to divest its Food Solutions business for $670 million is a credit positive. There is no impact on LabCorp's Baa2 ratings or stable outlook. For additional inform...

Laboratory Corporation of America Holdings: LabCorp's divestiture of Food Solutions business is credit positive

LabCorp's divestiture of Covance Food Solutions business will help in further reducing leverage.

LAB CORP OF AMERICA reduces its risk exposure and slightly improves to Neutral

The independent financial analyst theScreener just allocated a lower risk rating to LAB CORP OF AMERICA (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date July 24, 2020, the closing price was USD 198.74 and its expected value was estimated at USD 175.76.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch